No mutations or genomic rearrangements were observed in known NSCLC driver genes, including EGFR and ALK—consistent with the diagnostic workup—KRAS, ROS1, HER2, RET, or BRAF.32 A MET exon 14 splice site mutation (c.3028G>A) was observed in both the primary tumor and metastasis and was associated with MET amplification. The gene discussed is ROS1; the disease is neoplasm.